{"transactions":[{"id":729181,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T20:27:51.000Z","date":"2026-06-21","kind":"grant","planned":false,"acquired":true,"shares":4200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":4200,"derivative":{"exercise_price":8.1,"expiration_date":"2036-06-20","underlying":"Common Stock","underlying_shares":4200},"source":{"system":"sec-edgar","filing":"0001762451-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000002/ownership.xml","form_type":"4"}},{"id":775132,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":5.25,"expiration_date":"2033-05-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":775131,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":5.03,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":775130,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":2.55,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":775129,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2124,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":15.3,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":2124},"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":775128,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":33.6,"expiration_date":"2031-01-08","underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":775127,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":51.15,"expiration_date":"2030-05-18","underlying":"Common Stock","underlying_shares":635},"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":775126,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":823,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":39.45,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":823},"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":775125,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation."}],"balance_after":0,"derivative":{"exercise_price":23.55,"expiration_date":"2028-12-21","underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":775124,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T20:47:33.000Z","date":"2026-05-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10491,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Certain of these shares are represented by previously reported restricted stock units (\"RSUs\"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the \"Company\"), Neocrine Biosciences, Inc. (\"Parent\") and Sigma Merger Sub, Inc. (\"Merger Sub\"), on May 18, 2026, Merger Sub merged with and into the Company (the \"Merger\"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001762451-26-000001","document":"form4-05182026_080529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000176245126000001/form4-05182026_080529.xml","form_type":"4"}},{"id":1111771,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:04:26.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":26400,"derivative":{"exercise_price":0.78,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0000950170-25-086135","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017025086135/ownership.xml","form_type":"4"}},{"id":1111770,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:04:26.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":17700,"source":{"system":"sec-edgar","filing":"0000950170-25-086135","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017025086135/ownership.xml","form_type":"4"}},{"id":1118006,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T23:25:16.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":3991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 5, 2025 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU."}],"balance_after":10491,"source":{"system":"sec-edgar","filing":"0001415889-25-016360","document":"form4-06092025_110614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000141588925016360/form4-06092025_110614.xml","form_type":"4"}},{"id":1424342,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":26400,"derivative":{"exercise_price":5.195,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424341,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424340,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":11.49,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424339,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424338,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":8172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":8172,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":8172},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424337,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":8172},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424336,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424335,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424334,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"grant","planned":false,"acquired":true,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":28828,"derivative":{"exercise_price":15.75,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1424333,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-23T20:08:41.000Z","date":"2024-08-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":2.14,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0000950170-24-100180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024100180/ownership.xml","form_type":"4"}},{"id":1485040,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T00:51:50.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001415889-24-016311","document":"form4-06112024_120646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000141588924016311/form4-06112024_120646.xml","form_type":"4"}},{"id":1486954,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:03:42.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":26400,"derivative":{"exercise_price":1.44,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0000950170-24-070575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024070575/ownership.xml","form_type":"4"}},{"id":1486953,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:03:42.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":11800,"source":{"system":"sec-edgar","filing":"0000950170-24-070575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000095017024070575/ownership.xml","form_type":"4"}},{"id":1805975,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":26400,"derivative":{"exercise_price":2.14,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805974,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.195,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805973,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":2.14,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805972,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":11.49,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805971,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":8172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on March 2, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":8172,"derivative":{"exercise_price":2.14,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":8172},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805970,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on March 2, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":8172},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805969,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":18500,"derivative":{"exercise_price":2.14,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805968,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805967,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"grant","planned":false,"acquired":true,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33% of the shares subject to this option vested and became exercisable on March 2, 2022, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":28828,"derivative":{"exercise_price":2.14,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1805966,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-16T22:07:52.000Z","date":"2023-08-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the \"Repricing\"), effective as of August 14, 2023 (the \"Effective Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33% of the shares subject to this option vested and became exercisable on March 2, 2022, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":15.75,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0001209191-23-046096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123046096/doc4.xml","form_type":"4"}},{"id":1870116,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T21:46:31.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":26400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":26400,"derivative":{"exercise_price":5.195,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":26400},"source":{"system":"sec-edgar","filing":"0001209191-23-033955","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123033955/doc4.xml","form_type":"4"}},{"id":1870115,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-02T21:46:31.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was issued Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance."}],"balance_after":5900,"source":{"system":"sec-edgar","filing":"0001209191-23-033955","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123033955/doc4.xml","form_type":"4"}},{"id":1876653,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-05-26T22:30:56.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option shall vest on November 26, 2023, subject to the Reporting Person continuing to be a Service Provider through such date."}],"balance_after":10000,"derivative":{"exercise_price":5.25,"expiration_date":"2033-05-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-032697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123032697/doc4.xml","form_type":"4"}},{"id":1876652,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-05-26T22:30:56.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":2666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of May 25, 2023 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date."}],"balance_after":2666,"derivative":{"exercise_price":5.03,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001209191-23-032697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919123032697/doc4.xml","form_type":"4"}},{"id":2137184,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-10-14T22:31:20.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":2666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022."}],"balance_after":2666,"derivative":{"exercise_price":2.55,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":2666},"source":{"system":"sec-edgar","filing":"0001209191-22-053698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919122053698/doc4.xml","form_type":"4"}},{"id":2217401,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2022-07-01T20:44:37.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":871125,"price":45.98,"value":40054327.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"At the effective time of the Merger, each warrant to purchase common stock of the Issuer (the \"Series A warrants\") that was outstanding as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to $45.98 per share of the Issuer's common stock subject to the Series A warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":871125},"source":{"system":"sec-edgar","filing":"0001493152-22-018397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000149315222018397/ownership.xml","form_type":"4"}},{"id":2217400,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T20:44:37.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":18.11,"exercise_date":"2022-06-08","expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001493152-22-018397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000149315222018397/ownership.xml","form_type":"4"}},{"id":2217399,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T20:44:37.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":6874,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested as to 8.333% of the total shares monthly, commencing on July 9, 2020, and was fully vested at the effective time of the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.98,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":6874},"source":{"system":"sec-edgar","filing":"0001493152-22-018397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000149315222018397/ownership.xml","form_type":"4"}},{"id":2217398,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T20:44:37.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested in equal monthly installments over a period of 12 months commencing on December 29, 2019, and was fully vested at the effective time of the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.868,"expiration_date":"2029-11-29","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001493152-22-018397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000149315222018397/ownership.xml","form_type":"4"}},{"id":2217397,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2022-07-01T20:44:37.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1314127,"price":55,"value":72276985.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 12, 2022 (the \"Merger Agreement\"), between Sierra Oncology Inc. (the \"Issuer\"), GlaxoSmithKline plc (\"GSK\"), and Orikum Acquisition Inc. (\"Acquisition Sub\"). On July 1, 2022, upon the closing of the merger of Acquisition Sub with and into the Issuer (the \"Merger\") contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $55.00, without interest and less any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-22-018397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000149315222018397/ownership.xml","form_type":"4"}},{"id":2244945,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:41:13.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":18500,"derivative":{"exercise_price":11.49,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-22-034097","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919122034097/doc4.xml","form_type":"4"}},{"id":2313000,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-03-31T21:29:28.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":7720000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Soleno Therapeutics, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":7720000,"derivative":{"exercise_price":0.3,"exercise_date":"2022-03-29","expiration_date":"2027-03-29","underlying":"Common Stock","underlying_shares":7720000},"source":{"system":"sec-edgar","filing":"0000905718-22-000521","document":"solenoth_fm4mar292022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571822000521/solenoth_fm4mar292022.xml","form_type":"4"}},{"id":2312999,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-31T21:29:28.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":7720000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Soleno Therapeutics, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":18022602,"source":{"system":"sec-edgar","filing":"0000905718-22-000521","document":"solenoth_fm4mar292022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571822000521/solenoth_fm4mar292022.xml","form_type":"4"}},{"id":2419397,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2022-02-01T22:04:10.000Z","date":"2022-01-28","kind":"other","acquired":false,"shares":287471,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each Series B warrant will expire on the 75th day anniversary of the Issuer's announcement of top-line data from its MOMENTUM Phase 3 clinical trial of momelotinib."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":287471},"source":{"system":"sec-edgar","filing":"0000905718-22-000178","document":"sierraonco_fm4jan282022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571822000178/sierraonco_fm4jan282022.xml","form_type":"4"}},{"id":2419396,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2022-02-01T22:04:10.000Z","date":"2022-01-31","kind":"purchase","acquired":true,"shares":150000,"price":27,"value":4050000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1314127,"source":{"system":"sec-edgar","filing":"0000905718-22-000178","document":"sierraonco_fm4jan282022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571822000178/sierraonco_fm4jan282022.xml","form_type":"4"}},{"id":2419395,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2022-02-01T22:04:10.000Z","date":"2022-01-28","kind":"other","acquired":true,"shares":287471,"price":13.2,"value":3794617.2,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1164127,"source":{"system":"sec-edgar","filing":"0000905718-22-000178","document":"sierraonco_fm4jan282022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571822000178/sierraonco_fm4jan282022.xml","form_type":"4"}},{"id":2475654,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-13T23:00:27.000Z","date":"2021-12-08","kind":"purchase","acquired":true,"shares":500000,"price":14,"value":7000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on December 10, 2021. These shares are held by Abingworth Bioventures 8 LP (\"ABV 8\"). Abingworth Bioventures 8 GP LP (\"Abingworth GP\") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP (\"Abingworth GP 8\"), serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP 8) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. The Reporting Person is a member of the investment committee of ABV 8. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV 8 to employees of Abingworth LLP, subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2115385,"source":{"system":"sec-edgar","filing":"0000905718-21-001591","document":"adicetbio_fm4amdec82021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571821001591/adicetbio_fm4amdec82021.xml","form_type":"4/A","original_submission_date":"2021-12-10"}},{"id":2477343,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-10T22:30:24.000Z","date":"2021-12-08","kind":"purchase","acquired":true,"shares":500000,"price":14,"value":7000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares were purchased from the underwriters in a firm-commitment underwritten public offering of shares of the Issuer's common stock that closed on December 10, 2021. These shares are held by Abingworth Bioventures 8 LP (\"ABV 8\"). Abingworth Bioventures 8 GP LP (\"Abingworth GP\") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP (\"Abingworth GP 8\"), serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP 8) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. The Reporting Person is a member of the investment committee of ABV 8. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV 8 to employees of Abingworth LLP, subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2140721,"source":{"system":"sec-edgar","filing":"0000905718-21-001587","document":"adicetbio_fm4dec82021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571821001587/adicetbio_fm4dec82021.xml","form_type":"4"}},{"id":2608610,"issuer":{"id":74409,"kind":"organization","name":"Verona Pharma plc","symbol":"VRNA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to Buy)","published_at":"2021-08-10T20:42:40.000Z","date":"2021-08-09","kind":"grant","acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares (\"ADSs\"), each of which represents eight (8) Ordinary Shares of the Issuer."}],"balance_after":64000,"derivative":{"exercise_price":0.775,"expiration_date":"2031-08-08","underlying":"Ordinary Shares","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0001104659-21-102888","document":"tm2124631-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000110465921102888/tm2124631-2_4seq1.xml","form_type":"4"}},{"id":2675921,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2021-06-09T14:24:15.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option fully vests and becomes exercisable on June 8, 2022, subject to the Reporting Person's provision of service to the Issuer as of the vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person is a Partner of Abingworth LLP (\"ALLP\"). ALLP provides advisory services to Abingworth Bioventures VII, LP (\"ABV VII\"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of ALLP."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"ABV VII may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VII or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6000,"derivative":{"exercise_price":18.11,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-21-039087","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919121039087/doc4.xml","form_type":"4"}},{"id":2681099,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-06-04T20:29:14.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":31862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":31862,"derivative":{"exercise_price":1.02,"expiration_date":"2021-06-01","underlying":"Common Stock","underlying_shares":31862},"source":{"system":"sec-edgar","filing":"0000899243-21-022038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000089924321022038/doc4.xml","form_type":"4"}},{"id":2730395,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-04T23:26:22.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":8172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares shall vest in thirty-six (36) equal monthly installments beginning March 2, 2021."}],"balance_after":8172,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":8172},"source":{"system":"sec-edgar","filing":"0001209191-21-030102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919121030102/doc4.xml","form_type":"4"}},{"id":2730394,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-04T23:26:22.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":18500,"derivative":{"exercise_price":15.93,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-21-030102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000120919121030102/doc4.xml","form_type":"4"}},{"id":2786530,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-16T23:07:28.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"33% of the shares shall become exercisable on March 2, 2022, and the remaining 67% of the shares shall vest in 24 equal monthly installments thereafter."}],"balance_after":28828,"derivative":{"exercise_price":15.75,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0000899243-21-012024","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000089924321012024/doc4a.xml","form_type":"4/A","original_submission_date":"2021-03-04"}},{"id":2809103,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-04T22:18:21.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":28828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"33% of the shares shall become exercisable on March 2, 2022, and the remaining 67% of the shares shall vest in 24 equal monthly installments thereafter."}],"balance_after":28828,"derivative":{"exercise_price":15.75,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":28828},"source":{"system":"sec-edgar","filing":"0000899243-21-009877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000089924321009877/doc4.xml","form_type":"4"}},{"id":2909721,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-01-13T02:41:17.000Z","date":"2021-01-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the Option shall be deemed vested on the Transaction Date (which is January 8, 2021)."}],"balance_after":40000,"derivative":{"exercise_price":2.24,"expiration_date":"2031-01-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-001764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000089924321001764/doc4.xml","form_type":"4"}},{"id":3089057,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-06T20:03:35.000Z","date":"2020-06-26","kind":"purchase","acquired":true,"shares":3333330,"price":1.65,"value":5499994.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP,"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":10302602,"source":{"system":"sec-edgar","filing":"0000905718-20-000724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571820000724/ownership.xml","form_type":"4"}},{"id":3114939,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy","published_at":"2020-06-10T20:05:19.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":6874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 8.333% of the total shares monthly, beginning on July 9, 2020, with 100% of the total shares vested and exercisable on June 9, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":6874,"derivative":{"exercise_price":13.98,"expiration_date":"2030-06-09","underlying":"Common Stock $.001 par value","underlying_shares":6874},"source":{"system":"sec-edgar","filing":"0000905718-20-000564","document":"sierraonco_fm4jun92020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571820000564/sierraonco_fm4jun92020.xml","form_type":"4"}},{"id":3141013,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2020-05-20T21:47:21.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":9530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is May 18, 2020) or the day before the 2020 Annual Shareholder Meeting, whichever is earlier."}],"balance_after":9530,"derivative":{"exercise_price":3.41,"expiration_date":"2030-05-18","underlying":"Common Stock","underlying_shares":9530},"source":{"system":"sec-edgar","filing":"0000899243-20-013720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000089924320013720/doc4.xml","form_type":"4"}},{"id":3295033,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-02-03T21:14:52.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":11500,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F5","text":"Consists of 11,500 shares of Series A Preferred Stock held by ABV VII which are convertible into an aggregate of 871,240 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":871240},"source":{"system":"sec-edgar","filing":"0000905718-20-000101","document":"sierraonco_fm4ajan312020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571820000101/sierraonco_fm4ajan312020.xml","form_type":"4/A","original_submission_date":"2020-01-31"}},{"id":3295032,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-03T21:14:52.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":871240,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":876656,"source":{"system":"sec-edgar","filing":"0000905718-20-000101","document":"sierraonco_fm4ajan312020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571820000101/sierraonco_fm4ajan312020.xml","form_type":"4/A","original_submission_date":"2020-01-31"}},{"id":3296802,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-02-01T01:15:17.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":11500,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F5","text":"Consists of 11,500 shares of Series A Preferred Stock held by ABV VII which are convertible into an aggregate of 871,125 shares of Common Stock, as adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":871125},"source":{"system":"sec-edgar","filing":"0000905718-20-000098","document":"sierraonco_fm4jan292020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571820000098/sierraonco_fm4jan292020.xml","form_type":"4"}},{"id":3296801,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-01T01:15:17.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":871125,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of Sierra Oncology, Inc. (the \"Issuer\") are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":876542,"source":{"system":"sec-edgar","filing":"0000905718-20-000098","document":"sierraonco_fm4jan292020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571820000098/sierraonco_fm4jan292020.xml","form_type":"4"}},{"id":3354395,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-03T21:39:49.000Z","date":"2019-11-29","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of Sierra Oncology, Inc.'s 2015 Equity Incentive Plan (the \"2015 Plan\"). The option vests in equal monthly installments over a period of 12 months commencing on December 29, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2015 Plan."}],"balance_after":60000,"derivative":{"exercise_price":0.3467,"expiration_date":"2029-11-29","underlying":"Common Stock $.001 par value","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000905718-19-000975","document":"sierraonco_fm4nov2019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571819000975/sierraonco_fm4nov2019.xml","form_type":"4"}},{"id":3386332,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-29T20:01:55.000Z","date":"2019-10-25","kind":"purchase","acquired":true,"shares":2300000,"price":1.2,"value":2760000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":6969272,"source":{"system":"sec-edgar","filing":"0000905718-19-000875","document":"soleno_fm4oct252019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571819000875/soleno_fm4oct252019.xml","form_type":"4"}},{"id":3492913,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2019-06-12T21:39:48.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the Option shall vest on the one year anniversary of the Transaction Date (which is June 10, 2019) or the day before the 2019 Annual Shareholder Meeting, whichever is earlier."}],"balance_after":13000,"derivative":{"exercise_price":2.5,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000899243-19-016671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000089924319016671/doc4.xml","form_type":"4"}},{"id":3717644,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-12-27T21:08:47.000Z","date":"2018-12-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 21, 2018 with respect to 20,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on December 21, 2018."}],"balance_after":20000,"derivative":{"exercise_price":1.57,"expiration_date":"2028-12-21","underlying":"Common Stock $.001 par value","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000905718-18-000995","document":"soleno_fm4dec212018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571818000995/soleno_fm4dec212018.xml","form_type":"4"}},{"id":3717643,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant","published_at":"2018-12-27T21:08:47.000Z","date":"2018-12-21","kind":"purchase","acquired":true,"shares":4669272,"price":0.0062,"value":28949.4864,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4669272,"derivative":{"exercise_price":2,"exercise_date":"2018-12-21","expiration_date":"2023-12-21","underlying":"Common Stock $.001 par value","underlying_shares":233463},"source":{"system":"sec-edgar","filing":"0000905718-18-000995","document":"soleno_fm4dec212018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571818000995/soleno_fm4dec212018.xml","form_type":"4"}},{"id":3717642,"issuer":{"id":46432,"kind":"organization","name":"SOLENO THERAPEUTICS INC","symbol":"SLNO"},"owners":[{"id":35996,"kind":"person","name":"Sinclair Andrew","position":1,"cik":"0001762451","reported_name":"Sinclair Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-27T21:08:47.000Z","date":"2018-12-21","kind":"purchase","acquired":true,"shares":4669272,"price":1.6,"value":7470835.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by Abingworth Bioventures VII, LP (\"ABV VII\"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":4669272,"source":{"system":"sec-edgar","filing":"0000905718-18-000995","document":"soleno_fm4dec212018.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762451/000090571818000995/soleno_fm4dec212018.xml","form_type":"4"}}]}